Analysts at Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ: RTTR) from Sell to Hold today.With a rating of Hold on the stock, the company has a 52-week high of $3.17. The one-year price target of $5.33 is above the opening price of $1.37, that has caused a fair amount of other analysts to comment on the stock in recent days. Usually, after analysts give an upgrade report on a stock, they will later issue sporadic revisions, such as a price target change.
U.S. stocks on Monday closed essentially flat, after trading firmly higher, in a volatile session ahead of the start of a pair of closely watched central-bank policy meetings.
The Dow Jones Industrial Average DJIA, -0.02% closed down 3.63 points at 18,120.17.
The blue-chip index had been up by as much as 131 points earlier and traded within a 162-point range.
The S&P 500 SPX, +0.00% slipped 0.04 points to close at 2,139.12, after trading within an 18-point range
Meanwhile, the Nasdaq Composite Index COMP, -0.18% declined 9.54 points, or 0.2%, to close at 5,235.03.
Earlier, the index had been up by as many as 37 points and traded with a 58-point range
Shares of Ritter Pharmaceuticals Inc (NASDAQ: RTTR) opened at $1.37 yesterday and traded in a range between, $1.35 and $1.41, and last traded at $1.35, which is a drop of $0.06 compared to the previous closing price.
Ritter Pharmaceuticals Inc (NASDAQ: RTTR) now has a market cap of 11.59M.
31,676 shares traded hands yesterday, 65 percent below the norm, out of a total float 4,427,000. Momentum traders often use swings in trading volume to pinpoint substantial volume growth or circulation by institutional investors, so trading volume is likely to increase in the next few days.
While an increase in trading for short periods will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks delivers a positive cue to market traders that institutions may be moving in, so institutional sponsorship is very important.
Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.
Professional investors such as these retain substantial teams of analysts that research thousands of stocks, so it is good corroboration to see them buying a stock you’re considering.
By marking the activity of these professional investors and how they influence moving averages, traders are able to make make smarter trades.
Trades for Ritter Pharmaceuticals Inc (NASDAQ: RTTR) have ranged from $0.98 – 3.17, and the stock now has a 50-day MA of $1.34 and 200-day MA of $1.49. Today’s last price is 0.57% below the 52 week high of $3.17.
Earnings growth is an important factor to research when buying stocks and investors identify companies that have been successful at growing their earnings by at least 25% over 3 consecutive years.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.